Peplin completes Neosil buy
Monday, 20 October, 2008
Peplin has completed its US$6.7 million purchase of private dermatology company Neosil.
The Brisbane biotech issued shares iin common stock in exchange for all equity interests in Neosil, which is developing a topical hair growth product and a broad-spectrum topical anti-microbial agent for acne.
Peplin shareholders have also approved a private placement of stock to raise US$24 million to help fund its Phase III trial of PEP005, a topical gel for sun spots.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
